The DNA10K pilot program, which was unveiled earlier this year, is part of NorthShore’s partnership with Color, a Burlingame, Calif.-based population genomics company. New and existing NorthShore patients who opt into the program will receive free access to Color’s genetic testing and whole genome sequencing, which regularly retail for $249, as well as access to NorthShore and Color’s genetic counselors and clinical pharmacists.
Genomic test results will be integrated into each patient’s electronic health record and made available for review by NorthShore’s physicians in order to provide insight on genetic makeup, pharmacogenomics and risk factors for hereditary cancers and heart disease. This information will inform more personalized treatment plans to ensure better outcomes, prevention and overall health for each patient.
More articles about health IT:
Allina Health tests waters for apps based on patient journeys
U of Iowa researchers receive grant to study EHR information sharing patterns
Scientists close to identifying early-stage cancer using blood tests, oncology company CEO says
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
